BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Driescher C, Fuchs K, Haeberle L, Goering W, Frohn L, Opitz FV, Haeussinger D, Knoefel WT, Keitel V, Esposito I. Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer. Cancers (Basel) 2020;13:E39. [PMID: 33375555 DOI: 10.3390/cancers13010039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Liu Y, Fu J, Mugaanyi J, Yan J, Lu C, Huang J. Bile is a reliable and valuable source to study cfDNA in biliary tract cancers. Front Oncol 2022;12:961939. [DOI: 10.3389/fonc.2022.961939] [Reference Citation Analysis]
2 Liu S, Wang J. Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy. Curr Issues Mol Biol 2022;44:2695-709. [PMID: 35735625 DOI: 10.3390/cimb44060184] [Reference Citation Analysis]
3 Keup C, Kimmig R, Kasimir-bauer S. Combinatorial Power of cfDNA, CTCs and EVs in Oncology. Diagnostics 2022;12:870. [DOI: 10.3390/diagnostics12040870] [Reference Citation Analysis]
4 Baj J, Bryliński Ł, Woliński F, Granat M, Kostelecka K, Duda P, Flieger J, Teresiński G, Buszewicz G, Furtak-Niczyporuk M, Portincasa P. Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. Cancers (Basel) 2022;14:1493. [PMID: 35326644 DOI: 10.3390/cancers14061493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rizzo A, Ricci AD, Brandi G. Bile cell‑free DNA: a game changer for management of biliary tract cancer? ESMO Open 2022;7:100389. [PMID: 35121524 DOI: 10.1016/j.esmoop.2022.100389] [Reference Citation Analysis]
6 Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won J, Papageorgis P. Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers 2022;14:397. [DOI: 10.3390/cancers14020397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, De Miguel-Perez D, Denninghoff V, Durán I, Jantus-Lewintre E, Nuzzo PV, O'Byrne K, Pauwels P, Pickering EM, Raez LE, Russo A, Serrano MJ, Gandara DR, Troncone G, Rolfo C. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34570988 DOI: 10.1080/14737159.2021.1985468] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Han JY, Ahn KS, Kim TS, Kim YH, Cho KB, Shin DW, Baek WK, Suh SI, Jang BC, Kang KJ. Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer. Cancers (Basel) 2021;13:4581. [PMID: 34572808 DOI: 10.3390/cancers13184581] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
9 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]